JPH0599923A - Human-hemoglobin detecting method and feces melting buffer solution used therefor - Google Patents
Human-hemoglobin detecting method and feces melting buffer solution used thereforInfo
- Publication number
- JPH0599923A JPH0599923A JP29216391A JP29216391A JPH0599923A JP H0599923 A JPH0599923 A JP H0599923A JP 29216391 A JP29216391 A JP 29216391A JP 29216391 A JP29216391 A JP 29216391A JP H0599923 A JPH0599923 A JP H0599923A
- Authority
- JP
- Japan
- Prior art keywords
- feces
- human hemoglobin
- liquid
- buffer solution
- detected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は抗ヒトヘモグロビン抗体
を用いた免疫学的なヒトヘモグロビン検出方法に関し、
特に糞便を含む被検液中に存在するヒトヘモグロビンを
高感度にて検出することができる方法、及びそれに用い
る便溶解用緩衝液に関する。TECHNICAL FIELD The present invention relates to an immunological method for detecting human hemoglobin using an anti-human hemoglobin antibody,
In particular, the present invention relates to a method capable of detecting human hemoglobin present in a test solution containing feces with high sensitivity, and a stool lysis buffer used therein.
【０００２】[0002]
【従来の技術】近年、大腸癌などの下部消化器の疾患を
検査する方法として、消化器管からの出血に起因する糞
便中の潜血成分、特にヒトヘモグロビンの検出が主に行
われている。中でも、食品摂取や薬剤投与の制限を必要
としない、抗ヒトヘモグロビン抗体を用いた免疫学的な
検出方法が提案されている。2. Description of the Related Art In recent years, detection of occult blood components in feces caused by bleeding from the digestive tract, particularly human hemoglobin, has been mainly performed as a method for examining diseases of the lower digestive organs such as colon cancer. Above all, an immunological detection method using an anti-human hemoglobin antibody, which does not require food intake or drug administration, has been proposed.
【０００３】このような検出方法には例えば、寒天板内
での抗ヒトヘモグロビン抗体と、被検液中のヒトヘモグ
ロビンとの沈降線を利用してヘモグロビンを検出する一
次元免疫拡散法や、動物血球に抗ヒトヘモグロビン抗体
を感作したものと、被検液とを混合して生じる沈降現象
像を利用して検出する逆受身血球凝集法、高分子ラテッ
クス粒子に抗ヒトヘモグロビン抗体を感作したものと、
被検液を混合して生じる凝集像を利用して検出するラテ
ックス凝集法、酵素や放射性同位元素で標識した抗ヒト
ヘモグロビン抗体を利用する酵素免疫法や放射免疫法な
どがある。Such detection methods include, for example, a one-dimensional immunodiffusion method for detecting hemoglobin by utilizing the precipitation line between an anti-human hemoglobin antibody in an agar plate and human hemoglobin in a test solution, and an animal. Reverse passive hemagglutination method, in which blood cells were sensitized with anti-human hemoglobin antibody and the sedimentation phenomenon image generated by mixing with a test solution, and high-molecular latex particles were sensitized with anti-human hemoglobin antibody things and,
There are a latex agglutination method in which an agglutination image produced by mixing test liquids is used for detection, an enzyme immunoassay method in which an anti-human hemoglobin antibody labeled with an enzyme or a radioisotope is used, and a radioimmunoassay method.
【０００４】上記検出法においては被検物質であるヒト
ヘモグロビンは通常、溶解液状で検査に供され、例えば
便潜血検査では糞便を生理食塩水や緩衝液中に溶解する
事により、糞便中のヒトヘモグロビンを溶解液状態にし
て被検液として用いられている。[0004] In the above detection method, human hemoglobin, which is a test substance, is usually tested in a dissolved liquid state. For example, in a fecal occult blood test, human feces in feces are dissolved by dissolving feces in physiological saline or a buffer solution. It is used as a test liquid by making hemoglobin in a dissolved state.
【０００５】ヒトヘモグロビンの構造は、例えば、ヘモ
グロビンＡではアミノ酸141 個からなるα鎖とアミノ酸
146 個からなるβ鎖と呼ばれるポリペプチドが、それぞ
れ２個から形成してなる四量体であり、これらが立体構
造で配置されている。このような構造のヒトヘモグロビ
ンは糞便溶解液中で徐々に変性するために、従来から用
いられている免疫学的方法では検出感度が著しく低下す
るものである。特に、被検液中の糞便濃度が高い場合に
は上記ヒトヘモグロビンの変性が著しく、診断上、意義
のある低濃度領域での検出が困難となる。The structure of human hemoglobin is, for example, for hemoglobin A, an α chain consisting of 141 amino acids and amino acids.
A polypeptide called a β chain consisting of 146 is a tetramer formed of two, each of which is arranged in a three-dimensional structure. Since human hemoglobin having such a structure is gradually denatured in the fecal lysate, the detection sensitivity is remarkably lowered by the immunological methods used conventionally. In particular, when the fecal concentration in the test liquid is high, the human hemoglobin is significantly denatured, which makes it difficult to detect it in a low concentration region which is diagnostically significant.
【０００６】一方、便潜血検査では検査員の手間や不快
感を少なくするために、被検者自身が自宅などで糞便中
に含まれるヒトヘモグロビンを溶解液状態にする場合が
あり、このような場合は溶解液状態で数日間放置される
ことが多い。また、検査員がヒトヘモグロビンを溶解液
状態にした場合でも、作業の都合上、検査までに数時間
放置される場合もあり、このような放置状態では前述の
ようにヒトヘモグロビンの変性が起こってしまい好まし
くない。On the other hand, in the fecal occult blood test, in order to reduce the labor and discomfort of the inspector, the subject himself / herself sometimes puts human hemoglobin contained in the feces at home or the like into a solution state. In many cases, it is often left in a dissolved state for several days. Even if the inspector puts human hemoglobin in a dissolved state, it may be left for several hours before the test for the convenience of work, and in such an abandoned state, human hemoglobin is denatured as described above. It is not desirable.
【０００７】また、酵素免疫法のような検出方法を採用
した場合、高温度下で数分間上記溶解液をインキュベー
トすることがあり、やはりヒトヘモグロビンの変性によ
って正確な検出が困難となる。このようなヒトヘモグロ
ビンの変性を防止する目的で、例えばウシ血清アルブミ
ンや糖類などを添加することが行われているが、充分に
効果を発揮できるものとはいえないのが実情である。When a detection method such as an enzyme immunoassay is adopted, the above-mentioned lysate may be incubated at high temperature for several minutes, and denaturation of human hemoglobin makes accurate detection difficult. For the purpose of preventing such denaturation of human hemoglobin, for example, bovine serum albumin, saccharides, etc. have been added, but the fact is that the effect cannot be fully exerted.
【０００８】[0008]
【発明が解決しようとする課題】本発明は上記従来の技
術の欠点を解決するためになされたものであって、その
目的とするところは糞便を含有する被検液中に存在する
ヒトヘモグロビンの放置下での変性を防止しながら、か
つ、高感度で正確にヒトヘモグロビンを検出できる方
法、およびこれに用いる便溶解用緩衝液を提供すること
にある。SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned drawbacks of the prior art, and its object is to analyze human hemoglobin present in a test liquid containing feces. It is intended to provide a method capable of accurately detecting human hemoglobin with high sensitivity while preventing denaturation under standing and a stool lysis buffer used therefor.
【０００９】[0009]
【課題を解決するための手段】即ち、本発明は、抗ヒト
ヘモグロビン抗体を用いたヒトヘモグロビンの検出にお
いて、キレート試薬を被検液中に添加することを特徴と
する検出方法およびこれに用いる便溶解用緩衝液に関す
る。Means for Solving the Problems That is, the present invention provides a method for detecting human hemoglobin using an anti-human hemoglobin antibody, which comprises adding a chelating reagent to a test solution and a stool used for the same. It relates to a lysis buffer.
【００１０】本発明の方法において被検体としてのヒト
ヘモグロビンもしくはヒトヘモグロビンを含有する糞便
を溶解するための液としては、例えばりん酸緩衝液、グ
リシン緩衝液、トリス−塩酸緩衝液、ほう酸緩衝液など
がベース液として用いられる。緩衝液のｐＨは６〜９、
好ましくは６．５〜８．５の範囲とする。緩衝液中には
生理食塩濃度近傍の食塩を添加することが好ましい。ま
た、細菌などによるヒトヘモグロビンの変性を抑制する
ために、０．０５〜０．５重量％濃度のアジ化ナトリウ
ムなどの抗菌剤を添加することが好ましい。In the method of the present invention, examples of the liquid for dissolving human hemoglobin or feces containing human hemoglobin as a subject include, for example, phosphate buffer, glycine buffer, Tris-HCl buffer, borate buffer, etc. Is used as the base liquid. The pH of the buffer is 6-9,
The range is preferably 6.5 to 8.5. It is preferable to add salt having a physiological salt concentration close to that in the buffer solution. Further, in order to suppress denaturation of human hemoglobin by bacteria and the like, it is preferable to add an antibacterial agent such as sodium azide at a concentration of 0.05 to 0.5% by weight.
【００１１】本発明の方法においては上記緩衝液中にキ
レート試薬を添加し、ヒトヘモグロビンの変性を抑制す
る。本発明にて用いるキレート試薬としては、Ethylene
diamine tetraacetic acid（以下、ＥＤＴＡという）
や、Trans-1,2-Cyclohexanediamine-N,N,N',N'-tetraac
etic acid,monohydeate 、N,N-Di(hydroxyethyl)glycin
e 、Ethylenediamine-N,N'-diacetic acid、Ethylenedi
amine-N,N'-dipropionicacid,dihydrochloride、Ethyle
nediamine-N,N,N',N'-TETRAKis(methylenephosphonic a
cid)、Glycoletherdiamine-N,N,N',N'-tetraacetic aci
d 、Hexamethylenediamine-N,N,N',N'-tetraacetic aci
d 、Hydroxyethyliminodiacetic acid、Iminodiacetic
acid、1,2-Diaminopropane-N,N,N',N'-tetraacetic aci
d、Nitrilotriacetic acid （以下、ＮＴＡという）、N
itrilotripropionic acid、Nitrilotris(methylenephos
phonic acid)trisodium salt など、およびその金属塩
を用いることができる。キレート試薬の添加量は被検液
中の糞便の濃度によって適宜設定するが、糞便濃度４ｍ
ｇ／ｍｌの場合、０．０１ｍｍｏｌ／ｌ以上、好ましく
は０．１〜５０ｍｍｏｌ／ｌの濃度となるように添加す
る。添加量が少なすぎるとヒトヘモグロビンの変性を抑
制する作用が充分でなくなり好ましくなく、また多すぎ
ると増量効果が認められず不経済であると共に、溶解し
がたくなる。In the method of the present invention, a chelating agent is added to the above buffer solution to suppress the denaturation of human hemoglobin. As the chelating reagent used in the present invention, Ethylene
diamine tetraacetic acid (hereinafter referred to as EDTA)
Or Trans-1,2-Cyclohexanediamine-N, N, N ', N'-tetraac
etic acid, monohydeate, N, N-Di (hydroxyethyl) glycin
e, Ethylenediamine-N, N'-diacetic acid, Ethylenedi
amine-N, N'-dipropionicacid, dihydrochloride, Ethyle
nediamine-N, N, N ', N'-TETRAKis (methylenephosphonic a
cid), Glycoletherdiamine-N, N, N ', N'-tetraacetic aci
d, Hexamethylenediamine-N, N, N ', N'-tetraacetic aci
d, Hydroxyethyliminodiacetic acid, Iminodiacetic
acid, 1,2-Diaminopropane-N, N, N ', N'-tetraacetic aci
d, Nitrilotriacetic acid (hereinafter referred to as NTA), N
itrilotripropionic acid, Nitrilotris (methylenephos
Phonic acid) trisodium salt and the like, and metal salts thereof can be used. The addition amount of the chelating reagent is appropriately set according to the concentration of feces in the test liquid, but the fecal concentration is 4 m.
In the case of g / ml, the concentration is 0.01 mmol / l or more, preferably 0.1 to 50 mmol / l. If the amount added is too small, the effect of suppressing the denaturation of human hemoglobin will be insufficient, which is not preferable. If the amount added is too large, the effect of increasing the amount will not be observed, which is uneconomical and difficult to dissolve.
【００１２】本発明の方法では上記のようにしてキレー
ト試薬を添加した緩衝液中に、被検物質であるヒトヘモ
グロビンもしくはヒトヘモグロビンを含有する糞便を溶
解して被検液とする。具体的には、便潜血検査の場合、
被検者の糞便の一定量をキレート試薬を含有する一定量
の緩衝液中に溶解することにより調製することができ
る。In the method of the present invention, human hemoglobin as a test substance or feces containing human hemoglobin is dissolved in a buffer solution to which a chelating reagent has been added as described above to obtain a test liquid. Specifically, in case of fecal occult blood test,
It can be prepared by dissolving a fixed amount of feces of a subject in a fixed amount of a buffer solution containing a chelating reagent.
【００１３】本発明の検出方法を実施するには、従来か
ら知られている抗ヒトヘモグロビン抗体を用いた免疫学
的検出方法が採用できる。To carry out the detection method of the present invention, a conventionally known immunological detection method using an anti-human hemoglobin antibody can be adopted.
【００１４】以下にラテックス凝集法を利用した検出方
法について例示する。精製したヘモグロビンＡを抗原と
してウサギ、ヤギなどの動物に免疫したのち、採血、精
製をして抗ヒトヘモグロビン抗体を得る。この抗体を中
性ｐＨでポリスチレンラテックス（粒径０．３μｍ) と
混合して数時間吸着反応させたのち、ウシ血清アルブミ
ンおよび食塩を含む緩衝液などで遠心分離精製を行い、
抗ヒトヘモグロビン抗体感作ラテックス試薬を得る。An example of the detection method using the latex agglutination method will be described below. Animals such as rabbits and goats are immunized with the purified hemoglobin A as an antigen, and then blood is collected and purified to obtain anti-human hemoglobin antibody. This antibody was mixed with polystyrene latex (particle size 0.3 μm) at neutral pH and adsorbed and reacted for several hours, followed by centrifugal purification with a buffer solution containing bovine serum albumin and sodium chloride,
An anti-human hemoglobin antibody-sensitized latex reagent is obtained.
【００１５】次に、このラテックス試薬と被検液とをガ
ラス板上で撹拌混合し、数分後のラテックスの凝集像に
よって、ヒトヘモグロビンを定性的に検出することがで
きる。Next, the latex reagent and the test solution are mixed by stirring on a glass plate, and human hemoglobin can be qualitatively detected from the agglutination image of the latex after several minutes.
【００１６】また、酵素免疫法の場合は、抗ヒトヘモグ
ロビン抗体を感作したマイクロプレートのウエルに被検
液を入れ、洗浄した後、ペルオキシダーゼやアルカリフ
ォスファターゼで標識した抗体を添加し、発色度合いを
測定する。In the case of the enzyme immunoassay, the test solution is placed in the wells of a microplate sensitized with an anti-human hemoglobin antibody, and after washing, an antibody labeled with peroxidase or alkaline phosphatase is added to adjust the degree of color development. taking measurement.
【００１７】[0017]
【実施例】以下に本発明の実施例を示し、さらに具体的
に説明する。EXAMPLES Examples of the present invention will be shown below and will be described more specifically.
【００１８】実施例 ０．２ｍｏｌ／ｌグリシン、０．１％ウシ血清アルブミ
ン、０．１％アジ化ナトリウム、０．９％塩化ナトリウ
ムからなる水溶液を作製したのち、この溶液に表１中に
記載のキレート試薬を濃度を変えて溶解し、１Ｎ水酸化
ナトリウム水溶液にてｐＨ８．０に調整した。Example 1 An aqueous solution consisting of 0.2 mol / l glycine, 0.1% bovine serum albumin, 0.1% sodium azide and 0.9% sodium chloride was prepared, and this solution was described in Table 1. The chelating reagent of was dissolved in various concentrations and adjusted to pH 8.0 with a 1N aqueous sodium hydroxide solution.
【００１９】次に、５％カルボキシル化ポリスチレンラ
テックス１０ｍｌに１ｍｇ／ｍｌの１- エチル- ３-(３
- ジメチルアミノプロピル）カルボジイミド１０ｍｌを
加え、２０分間撹拌しながら反応させた後、０．０１ｍ
ｏｌ／ｌほう酸緩衝液（ｐＨ８．０）で２回遠心分離精
製した。Next, 1 mg / ml of 1-ethyl-3- (3 was added to 10 ml of 5% carboxylated polystyrene latex.
-Dimethylaminopropyl) carbodiimide (10 ml) was added and reacted for 20 minutes with stirring.
The product was centrifuged and purified twice with an ol / l borate buffer solution (pH 8.0).
【００２０】このラテックス（濃度５％）１０ｍｌに、
精製ヒトヘモグロビンをウサギに免疫して作製した抗ヒ
トヘモグロビン抗体（ウサギＩｇＧ、濃度５ｍｇ／ｍ
ｌ）７ｍｌを添加し、５時間ゆっくりと撹拌しながら反
応させ、さらに０．１％ウシ血清アルブミンを含む０．
０１ｍｏｌほう酸緩衝液（ｐＨ８．０）で３回遠心分離
精製し、ラテックス濃度１％の抗ヒトヘモグロビン抗体
感作ラテックス試薬を得た。To 10 ml of this latex (concentration 5%),
Anti-human hemoglobin antibody prepared by immunizing rabbits with purified human hemoglobin (rabbit IgG, concentration 5 mg / m
l) 7 ml was added, the reaction was carried out for 5 hours with slow stirring, and 0.1% bovine serum albumin was added.
The product was centrifuged and purified three times with a 01 mol borate buffer solution (pH 8.0) to obtain an anti-human hemoglobin antibody-sensitized latex reagent having a latex concentration of 1%.
【００２１】次に、前記にて調製したキレート試薬溶解
溶液中にヒトヘモグロビンを濃度を変えて溶解し、さら
に健常人糞便を４ｍｇ／ｍｌ濃度で溶解し、この溶液８
０μｌと前記ラテックス試薬２０μｌとをウエル内で混
合、撹拌して、１０分後の凝集像を肉眼にて観察した。
その結果を表１に示す。表１から明らかなように、高感
度でヒトヘモグロビンを検出できることが判明した。Next, human hemoglobin was dissolved in the chelating reagent dissolution solution prepared above by changing the concentration thereof, and further, feces of a healthy person was dissolved at a concentration of 4 mg / ml.
0 μl and 20 μl of the latex reagent were mixed in the well and stirred, and after 10 minutes, an agglutination image was visually observed.
The results are shown in Table 1. As is clear from Table 1, it was revealed that human hemoglobin can be detected with high sensitivity.
【００２２】次に、前記ヒトヘモグロビン溶解液を２５
℃で６日間放置した後、再び前記ラテックス試薬と混合
して凝集像を観察した。その結果を表２に示す。Next, 25 parts of the human hemoglobin solution was added.
After left at 6 ° C. for 6 days, the mixture was mixed with the latex reagent again, and an aggregation image was observed. The results are shown in Table 2.
【００２３】比較例 キレート試薬を添加しなかった以外は実施例と同様にし
てラテックス凝集反応を行い凝集像を観察した。その結
果を表１および表２に併記した。Comparative Example A latex agglutination reaction was carried out in the same manner as in Example except that the chelating reagent was not added, and an agglutination image was observed. The results are shown in Tables 1 and 2.
【００２４】＜凝集判定基準＞ ＋＋：非常に強い凝集がみられた。 ＋：強い凝集が
みられた。 ±：弱い凝集がみられた。 −：凝集がみられ
ない。<Criteria for Aggregation> ++: Very strong aggregation was observed. +: Strong aggregation was observed. ±: Weak aggregation was observed. -: No aggregation is observed.
【００２５】[0025]
【表１】 [Table 1]
【００２６】[0026]
【表２】 [Table 2]
【００２７】[0027]
【発明の効果】以上のように本発明の方法によれば、キ
レート試薬を被検液中に添加しているので、被検液中の
ヒトヘモグロビンが変性することを制御でき、その結
果、被検液を長時間放置する場合でも高感度にヒトヘモ
グロビンを検出することができるものである。As described above, according to the method of the present invention, since the chelating reagent is added to the test solution, it is possible to control the denaturation of human hemoglobin in the test solution. Human hemoglobin can be detected with high sensitivity even when the test liquid is left for a long time.
Claims (2)
モグロビンの検出において、キレート試薬を被検液中に
添加することを特徴とするヒトヘモグロビンの検出方
法。1. A method for detecting human hemoglobin, which comprises adding a chelating reagent to a test solution in the detection of human hemoglobin using an anti-human hemoglobin antibody.
ート試薬を含有することを特徴とする、被検体を溶解す
るための便溶解用緩衝液。2. A fecal lysis buffer for lysing an analyte, which contains a chelating reagent used for detecting human hemoglobin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29216391A JPH0599923A (en) | 1991-10-11 | 1991-10-11 | Human-hemoglobin detecting method and feces melting buffer solution used therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29216391A JPH0599923A (en) | 1991-10-11 | 1991-10-11 | Human-hemoglobin detecting method and feces melting buffer solution used therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0599923A true JPH0599923A (en) | 1993-04-23 |
Family
ID=17778366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29216391A Pending JPH0599923A (en) | 1991-10-11 | 1991-10-11 | Human-hemoglobin detecting method and feces melting buffer solution used therefor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0599923A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009051032A1 (en) | 2007-10-16 | 2009-04-23 | Eiken Chemical Co., Ltd. | Method of stabilizing hem protein and storage solution therefor |
| US10435735B2 (en) | 2014-03-07 | 2019-10-08 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
| US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| US11572581B2 (en) | 2002-06-07 | 2023-02-07 | DNA Genotek, Inc. | Compositions and methods for obtaining nucleic acids from sputum |
-
1991
- 1991-10-11 JP JP29216391A patent/JPH0599923A/en active Pending
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11572581B2 (en) | 2002-06-07 | 2023-02-07 | DNA Genotek, Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| AU2008313042B2 (en) * | 2007-10-16 | 2014-05-01 | Eiken Chemical Co., Ltd. | Method of stabilizing hem protein and storage solution therefor |
| US8445719B2 (en) | 2007-10-16 | 2013-05-21 | Eiken Chemical Co., Ltd. | Method of stabilizing heme protein and storage solution therefor |
| KR20100089845A (en) | 2007-10-16 | 2010-08-12 | 에이켄 케미컬 컴퍼니 리미티드 | Method of stabilizing hem protein and storage solution therefor |
| CN101828112A (en) * | 2007-10-16 | 2010-09-08 | 荣研化学株式会社 | Method of stabilizing hem protein and storage solution therefor |
| EP2944959A1 (en) | 2007-10-16 | 2015-11-18 | Eiken Chemical Co., Ltd. | Hemoglobin stabilizing storage solution |
| US8329943B2 (en) | 2007-10-16 | 2012-12-11 | Eiken Chemical Co., Ltd. | Method of stabilizing heme protein and storage solution therefor |
| EP2204648A1 (en) * | 2007-10-16 | 2010-07-07 | Eiken Chemical Co., Ltd. | Method of stabilizing hem protein and storage solution therefor |
| WO2009051032A1 (en) | 2007-10-16 | 2009-04-23 | Eiken Chemical Co., Ltd. | Method of stabilizing hem protein and storage solution therefor |
| EP2204648A4 (en) * | 2007-10-16 | 2010-12-08 | Eiken Chemical | Method of stabilizing hem protein and storage solution therefor |
| JP2009097956A (en) * | 2007-10-16 | 2009-05-07 | Eiken Chem Co Ltd | Heme protein stabilization method and preservation solution |
| US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| US11536632B2 (en) | 2011-06-19 | 2022-12-27 | DNA Genotek, Inc. | Biological collection system |
| US11549870B2 (en) | 2011-06-19 | 2023-01-10 | DNA Genotek, Inc. | Cell preserving solution |
| US11592368B2 (en) | 2011-06-19 | 2023-02-28 | DNA Genotek, Inc. | Method for collecting and preserving a biological sample |
| US11198899B2 (en) | 2014-03-07 | 2021-12-14 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
| US10435735B2 (en) | 2014-03-07 | 2019-10-08 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0720127A (en) | Method and reagent for measuring various pivka | |
| US4233286A (en) | Low affinity IGM-latex particles and assay therewith for immune complexes | |
| US4210622A (en) | Kit for assay of immune complexes | |
| US4118349A (en) | Process for the manufacture of polystyrene latex compounds | |
| US4141965A (en) | Assay of immune complexes | |
| CN107533050A (en) | The measure reagent and assay method of thrombin-antithrombin complex | |
| JP5317040B2 (en) | Method for immunological measurement of components in urine and reagent for use in the method | |
| JPH0599923A (en) | Human-hemoglobin detecting method and feces melting buffer solution used therefor | |
| JP2000258420A (en) | Stabilizing method of human-hemoglobin in solution and stabilizing solution | |
| JPH04145366A (en) | Detection of human hemoglobin and relative feces dissolving buffer solution | |
| JP2932837B2 (en) | Method for measuring human podocalyxin | |
| CN113109325A (en) | Pepsinogen I enzymatic chemiluminescence detection kit and preparation method and application thereof | |
| JP2654181B2 (en) | Detection method of human hemoglobin | |
| JPH11166932A (en) | Stabilization method for human hemoglobin | |
| JP2654932B2 (en) | C-reactive protein measurement reagent | |
| EP0100395B1 (en) | Reagent for determination of human urine kallikrein | |
| US4937201A (en) | Latex reagent for detection of the toxin of clostridium difficile | |
| JP4585708B2 (en) | Method and reagent for measuring substance forming complex | |
| JP2000206117A (en) | Method for stabilizing human hemoglobin | |
| JP4442340B2 (en) | Antibody, adsorbent containing the same, and immunoassay reagent | |
| JP2997723B2 (en) | Method for detecting human hemoglobin in feces | |
| JPH0313863A (en) | Method for measuring alpha1-antitrypsin in excrement using immunological latex agglutination reaction and reagent used for the method | |
| JPH03279859A (en) | Detection of human hemoglobin | |
| JPWO2008029873A1 (en) | Method for measuring antigen and antibody against the antigen, and measuring reagent used therefor | |
| WO1995029403A1 (en) | Method of assaying asialoglycoprotein receptor and assay reagent therefor |